Johnson & Johnson (JNJ) Inventory (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Inventory came in at $14.6 billion in Q1 2026, up 15.2% year-on-year from $12.7 billion in Q1 2025, and up 2.76% quarter-over-quarter from $14.2 billion in Q4 2025.
Johnson & Johnson (JNJ) Inventory (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Inventory across 18 years of filings, most recently posting $14.6 billion for Q1 2026.
- Inventory for Q1 2026 came in at $14.6 billion, up 15.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 billion (up 15.2% YoY), and the FY2025 annual result was $14.2 billion, up 14.04% from the prior year.
- Inventory came in at $14.6 billion for Q1 2026 at Johnson & Johnson, up from $14.2 billion in the prior quarter.
- In the past five years, Inventory ranged from a high of $14.6 billion in Q1 2026 to a low of $10.3 billion in Q1 2023.
- The 5-year median for Inventory is $12.3 billion (2024), against an average of $12.2 billion.
- Across the five-year window, Inventory rose 16.55% in 2023 and declined 11.13% in 2024, its largest moves.
- Johnson & Johnson's Inventory stood at $11.7 billion in 2022, then decreased by 4.23% to $11.2 billion in 2023, then grew by 11.3% to $12.4 billion in 2024, then rose by 14.04% to $14.2 billion in 2025, then advanced by 2.76% to $14.6 billion in 2026.
- The last three Inventory figures came in at $14.6 billion (Q1 2026), $14.2 billion (Q4 2025), and $14.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 8.30 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 14.53 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 14.58 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 5.05 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 6.48 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 6.19 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.91 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 10.67 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.76 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 14.58 Bn |
| Dec 28, 2025 | 14.19 Bn |
| Sep 28, 2025 | 14.15 Bn |
| Jun 29, 2025 | 13.41 Bn |
| Mar 30, 2025 | 12.66 Bn |
| Dec 29, 2024 | 12.44 Bn |
| Sep 29, 2024 | 12.60 Bn |
| Jun 30, 2024 | 12.17 Bn |
| Mar 31, 2024 | 11.38 Bn |
| Dec 31, 2023 | 11.18 Bn |
| Oct 1, 2023 | 11.20 Bn |
| Jul 2, 2023 | 12.89 Bn |
| Apr 2, 2023 | 12.81 Bn |
| Jan 1, 2023 | 10.27 Bn |
| Oct 2, 2022 | 11.68 Bn |
| Jul 3, 2022 | 11.44 Bn |
| Apr 3, 2022 | 10.99 Bn |
| Jan 2, 2022 | 10.39 Bn |
| Oct 3, 2021 | 10.39 Bn |
| Jul 4, 2021 | 10.10 Bn |